The Recall Desk

Severity 4 of 5

Severe recalls

The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.

What “severe” means here

Severity 4 (Severe) recalls have a real, documented risk of significant injury, hospitalization, or property damage even if no deaths have been reported. The agency classification is FDA Class II with hospitalization reports, USDA Class I, or a structural vehicle defect. These need attention quickly — not five-alarm urgency but not something to put off. Examples include allergen mislabeling on common allergens for products eaten by children, drug potency out of specification by a margin that could cause measurable harm, and vehicle defects affecting braking or steering.

The full rubric is on the methodology page. Severity is computed deterministically from the agency’s own classification plus the source text — no editorial vibes.

23351–23375 of 32176

  • SevereFDA (Drugs)·D-785-2015·2015-04-29

    Attix Pharmaceuticals Recalls Methotrexate Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Methotrexate Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Methotrexate Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-689-2015·2015-04-29

    Attix Pharmaceuticals Recalls Flutamide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Flutamide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Flutamide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-868-2015·2015-04-29

    Progesterone Soy Source Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Progesterone Soy Source active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Progesterone Soy Source active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-753-2015·2015-04-29

    Attix Pharmaceuticals Recalls Levalbuterol HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Levalbuterol HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Levalbuterol HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-777-2015·2015-04-29

    Attix Pharmaceuticals Recalls Melphalan API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Melphalan active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Melphalan active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-516-2015·2015-04-29

    Attix Pharmaceuticals Recalls Amitriptyline HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Amitriptyline HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Amitriptyline HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-796-2015·2015-04-29

    Attix Pharmaceuticals Recalls Mexiletine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Mexiletine HCl active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.

    Product
    Mexiletine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-700-2015·2015-04-29

    Glipizide API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Glipizide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Glipizide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-760-2015·2015-04-29

    Levosulpiride API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Levosulpiride active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Levosulpiride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-792-2015·2015-04-29

    Attix Pharmaceuticals Recalls Methylprednisolone Base Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Methylprednisolone Base active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Methylprednisolone Base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-597-2015·2015-04-29

    Attix Pharmaceuticals Recalls Clopidogrel Bisulfate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Clopidogrel Bisulfate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Clopidogrel Bisulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-714-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hydrocortisone Base Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of hydrocortisone base active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.

    Product
    Hydrocortisone base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-544-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bisacodyl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Bisacodyl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Bisacodyl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-800-2015·2015-04-29

    Attix Pharmaceuticals Recalls Minoxidil API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Minoxidil active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Minoxidil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-870-2015·2015-04-29

    Attix Pharmaceuticals Recalls Proparacaine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Proparacaine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Proparacaine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-941-2015·2015-04-29

    Attix Pharmaceuticals Recalls Trehalose Dihydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Trehalose Dihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Trehalose Dihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-593-2015·2015-04-29

    Attix Pharmaceuticals Recalls Clindamycin HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Clindamycin HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Clindamycin HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-565-2015·2015-04-29

    Attix Pharmaceuticals Recalls Carvedilol API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Carvedilol active pharmaceutical ingredient because it was repackaged in a facility with penicillin products without adequate separation, creating a cross-contamination risk.

    Product
    Carvedilol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-667-2015·2015-04-29

    Attix Pharmaceuticals Recalls Etravirine API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Etravirine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Etravirine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-798-2015·2015-04-29

    Miltefosine API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Miltefosine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Miltefosine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-715-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hydrocortisone Micronized Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hydrocortisone Micronized active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Hydrocortisone Micronized active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-730-2015·2015-04-29

    Attix Pharmaceuticals Recalls Imatinib Mesylate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Imatinib Mesylate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Imatinib Mesylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-910-2015·2015-04-29

    Tacrolimus Monohydrate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Tacrolimus Monohydrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Tacrolimus Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-697-2015·2015-04-29

    Attix Pharmaceuticals Recalls Gatifloxacin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Gatifloxacin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Gatifloxacin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-872-2015·2015-04-29

    Attix Pharmaceuticals Recalls Pyridostigmine Bromide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Pyridostigmine Bromide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Pyridostigmine Bromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide